Results 11 to 20 of about 2,928,478 (311)

Targeted cancer therapies [PDF]

Chinese Journal of Cancer, 2011
With unprecedented understanding of molecular events underlying human cancer in this genomic era, a large number of drugs specifically targeting hypothesized oncogenic drivers to which tumors are potentially addicted to have been developed and continue to be developed.
Yan, Li, Rosen, Neal, Arteaga, Carlos
openaire   +2 more sources

Individualizing cancer therapy [PDF]

Leukemia & Lymphoma, 2010
In this issue of Leukemia and Lymphoma, Ngo and colleagues describe the predictive value of cyclin D1 expression as a predictor of bortezomib response in multiple myeloma. The ability to predict treatment response based on genetic expression would be of value, if it could be confirmed in a larger study.
Morie A, Gertz, Tamar, Tadmor
openaire   +2 more sources

Fluorescent imaging for cancer therapy and cancer gene therapy [PDF]

Molecular Therapy - Oncolytics, 2021
The translation of laboratory science into effective clinical cancer therapy is gaining momentum more rapidly than any other time in history. Understanding cancer cell-surface receptors, cancer cell growth, and cancer metabolic pathways has led to many promising molecular-targeted therapies and cancer gene therapies.
Yanghee Woo, Shyambabu Chaurasiya, Michael O’Leary, Ernest Han, Yuman Fong   +4 more
openaire   +3 more sources

Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation

Radiation Oncology, 2019
Background We performed a prospective phase II study to compare acute toxicity among five different hypofractionated schedules using proton therapy. This study was an exploratory analysis to investigate the secondary end-point of biochemical failure-free
Boram Ha, Kwan Ho Cho, Kang Hyun Lee, Jae Young Joung, Yeon-Joo Kim, Sung Uk Lee, Hyunjung Kim, Yang-Gun Suh, Sung Ho Moon, Young Kyung Lim, Jong Hwi Jeong, Haksoo Kim, Weon Seo Park, Sun Ho Kim   +13 more
doaj   +1 more source

The use of hyperbaric oxygen to treat actinic rectal fistula after SpaceOAR use and radiotherapy for prostate cancer: a case report

BMC Urology, 2020
Background In definitive radiation therapy for prostate cancer, the SpaceOAR® System, a hydrogel spacer, is widely used to decrease the irradiated dose and toxicity of rectum.
Tairo Kashihara, Koji Inaba, Motokiyo Komiyama, Hiroki Nakayama, Kotaro Iijima, Shie Nishioka, Hiroyuki Okamoto, Nao Kikkawa, Yuko Kubo, Satoshi Shima, Satoshi Nakamura, Ayaka Takahashi, Kana Takahashi, Kae Okuma, Naoya Murakami, Hiroshi Igaki, Yuko Nakayama, Arinobu Fukunaga, Yoshiyuki Matsui, Hiroyuki Fujimoto, Jun Itami   +20 more
doaj   +1 more source

Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers

Radiation Oncology, 2023
Purpose The aim was to assess the feasibility of online adaptive radiotherapy (oART) for bladder cancer using a focal boost by focusing on the quality of the online treatment plan and automatic target delineation, duration of the workflow and performance
Sana Azzarouali, Karin Goudschaal, Jorrit Visser, Maarten Hulshof, Marjan Admiraal, Niek van Wieringen, Jakko Nieuwenhuijzen, Jan Wiersma, Laurien Daniëls, Duncan den Boer, Arjan Bel   +10 more
doaj   +1 more source

Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease; the identification of novel targets and development of effective treatment strategies are urgently needed to improve patient outcomes.
Olson, Michael F., Pajic, Marina, Rath, Nicola, Timpson, Paul, Vennin, Claire   +4 more
core   +1 more source

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. [PDF]

, 2017
Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated ...
Alshalalfa, Mohammed,, Bowden, Michaela,, Brown, Myles,, Davicioni, Elai,, Den, Robert B.,, Ellis, Leigh,, Eng, Kevin H.,, Erho, Nicholas,, Feng, Felix Y.,, Galbo, Phillip,, Goodrich, David W.,, Gray, Kathryn P.,, Huang, Ying,, Jenkins, Robert B.,, Karnes, R. Jeffrey,, Ku, Sheng Yu,, Labbé, David P.,, Lund University., Rosario, Spencer,, Ross, Ashley E., Schaeffer, Edward M.,, Sjöström, Martin,, Spratt, Daniel E.,, Sweeney, Christopher J.,, Wadosky, Kristine M.,   +24 more
core   +2 more sources

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

OncoImmunology, 2021
Cells in the tumor microenvironment of Follicular lymphoma (FL) express checkpoint molecules such as programmed death ligands 1 and 2 (PD-L1 and PD-L2) and are suppressing anti-tumor immune activity.
Uffe Klausen, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, Shamaila Munir Ahmad, Anne Ortved Gang, Evelina Martinenaite, Stine Emilie Weis-Banke, Marie Fredslund Breinholt, Guy Wayne Novotny, Julie Westerlin Kjeldsen, Morten Orebo Holmström, Lone Bredo Pedersen, Christian Bjørn Poulsen, Per Boye Hansen, Özcan Met, Inge Marie Svane, Carsten Utoft Niemann, Lars Møller Pedersen, Mads Hald Andersen   +18 more
doaj   +1 more source

The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]

, 2013
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S, Huang, Jiaoti, Zong, Yang   +2 more
core   +1 more source